Blood pressure changes during alemtuzumab infusion for multiple sclerosis patients-Reference-Cited by-同舟云学术

Blood pressure changes during alemtuzumab infusion for multiple sclerosis patients

Published:2020-12-05 Issue:4 Volume:28 Page:1396-1400
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Shosha Eslam¹^ORCID,Casserly Courtney¹,Tomkinson Christine¹,Morrow Sarah A.¹^ORCID

Affiliation:

1. Department of Clinical Neurological Sciences London Health Science CenterUniversity of Western Ontario (Western University London ON Canada

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.14633

Reference13 articles.

1. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

2. Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

3. Alemtuzumab CARE-MS II 5-year follow-up

4. US Food and Drug Administration.FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab) 2018. Safety Announc.https://www.fda.gov/downloads/Drugs/DrugSafety/UCM626584.pdf. Accessed 14 Mar 2019.

5. Intracerebral haemorrhage during alemtuzumab administration

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications;European Journal of Medical Research;2024-06-25

2. Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up;Heliyon;2024-03

3. Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis;Neurology;2024-02-13

4. Health, Wellness, and the Effect of Comorbidities on the Multiple Sclerosis Disease Course;Neurologic Clinics;2024-02

5. Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen;Multiple Sclerosis and Related Disorders;2022-10